IRIS
SIMONELLI, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2770
EU - Europa 599
AF - Africa 117
AS - Asia 69
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 5
OC - Oceania 2
Totale 3568
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2734
FI - Finlandia 124
NG - Nigeria 117
IT - Italia 113
FR - Francia 66
SE - Svezia 63
DE - Germania 61
IE - Irlanda 53
NL - Olanda 46
CA - Canada 36
GB - Regno Unito 29
TR - Turchia 29
BE - Belgio 25
IL - Israele 19
CN - Cina 9
CL - Cile 5
EU - Europa 4
CH - Svizzera 3
IR - Iran 3
PL - Polonia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AT - Austria 2
AU - Australia 2
ES - Italia 2
RU - Federazione Russa 2
BG - Bulgaria 1
IN - India 1
JP - Giappone 1
KR - Corea 1
MD - Moldavia 1
MK - Macedonia 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
UA - Ucraina 1
Totale 3568
Salva come PNG Salva come JPEG
Città #
Wilmington 706
Chandler 508
San Mateo 299
Ann Arbor 189
Lawrence 127
Princeton 127
Helsinki 124
Leawood 119
Benin City 117
Woodbridge 81
Paris 66
Milan 64
Fairfield 60
Dublin 53
Amsterdam 40
Toronto 35
Kocaeli 29
Brussels 25
London 25
Boardman 22
San Diego 21
Seattle 21
Norwalk 12
Abbiategrasso 8
Monmouth Junction 8
Des Moines 5
Nanjing 5
Redmond 5
Beijing 4
Falkenstein 4
Redwood City 4
Zwolle 4
Cambridge 3
Clearwater 3
Raleigh 3
Taipei 3
Almelo 2
Cupertino 2
Hanover 2
Phoenix 2
Poznan 2
Sacramento 2
Andover 1
Asbest 1
Ashburn 1
Augusta 1
Berlin 1
Borås 1
Buffalo 1
Chisinau 1
Genoa 1
Gorgonzola 1
Hockessin 1
Indianapolis 1
Jacksonville 1
Kemerovo 1
Köln 1
Leipzig 1
Manchester 1
Montréal 1
Pittsfield 1
Seoul 1
Torino 1
Valladolid 1
Vienna 1
Warsaw 1
Totale 2965
Salva come PNG Salva come JPEG
Nome #
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 54
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 48
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 47
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 47
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 45
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 45
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 44
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 44
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 44
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 43
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 43
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 43
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 43
Reproducibility of the WHO classification of thymomas: practical implications 43
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 42
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 41
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 41
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 40
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 40
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 40
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 40
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 39
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 39
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 39
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 39
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 39
COVID-19 and liver cancer clinical trials: not everything is lost 38
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 38
Neutrophils in Gliomas 38
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 38
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 38
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 37
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 37
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 36
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 36
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 36
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 35
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 34
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 34
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 34
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 33
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. 33
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 33
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 33
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 32
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 32
Advances in the biology of malignant pleural mesothelioma 31
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 31
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 31
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 30
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 30
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 30
Imaging biomarkers in primary brain tumours 30
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 30
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 30
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 30
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 29
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 29
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 29
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 29
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 28
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 28
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 28
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) 26
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 26
Future developments in the management of malignant pleural mesothelioma 26
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 26
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 26
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 26
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 25
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 25
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 25
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient A CARE-compliant case report 25
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 25
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 25
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 24
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 24
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 24
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 24
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial 24
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 24
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 24
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 24
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 24
Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis 24
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 23
Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study 23
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 23
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors 23
Newly diagnoses grade III glioma patients: evaluation of factors conditioning outcome 23
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours 23
IS SURGICAL RESECTION USEFUL IN ELDERLY NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? OUTCOME EVALUATION AND PROGNOSTIC FACTORS ASSESMENT 22
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 22
Phase Lib trial of tivantinib in combination with carboplatin and pernetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesotheliorna (MPM) 22
Vinorelbine as Second or Third-Line Therapy in Pemetrexed-Pretreated Malignant Pleural Mesothelioma (MPM) Patients 22
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours 22
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 22
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma 22
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) 22
Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 21
Totale 3201
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21359
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0000 00 00 00143
2020/20211426 4710198 11395 18499 28118517170
2021/2022689 32513139 46 28102 557119935
2022/20231535 28566162148 12099 3121 2651531130
Totale 3694